Citadel Advisors’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Citadel Advisors’s Portfolio MDNA Stock Details MDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-27,626	Closed	-$7.9K	–	15689
2023 Q3	$7.9K	Buy	+27,626	New	+$10.7K	﹤0.01%	13234
2021 Q3	–	Sell	-24,203	Closed	-$73K	–	14942
2021 Q2	$73K	Buy	+24,203	New	+$89.5K	﹤0.01%	13136

Other funds holding MDNA

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

NDSI

Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Citadel Advisors's MDNA Position: Q4 2023 in Review

Citadel Advisors sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2023, closing a stake of 27,626 shares — an estimated $7.9K sold.

Citadel Advisors first reported a position in MDNA in Q2 2021 and held it in 2 quarters. The position peaked at $73K in Q2 2021. 3 funds tracked by Wall St. Rank hold MDNA as of Q4 2023.

Citadel Advisors reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2023 after selling out during the quarter.
Citadel Advisors sold 27,626 Medicenna Therapeutics Corp. Common Shares shares in Q4 2023, an estimated $7.9K.
Citadel Advisors first reported a position in Medicenna Therapeutics Corp. Common Shares in Q2 2021 and held it in 2 quarters.
Citadel Advisors's Medicenna Therapeutics Corp. Common Shares position peaked at $73K in Q2 2021.
3 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.